Artificial nanoenzymes have shown promise in improving both the selectivity and efficacy of immunotherapy treatment. Only a small proportion of patients see the benefits of immunotherapy as tumour cells can employ a multitude of disguises to avoid detection by the immune system. Too ensure more patients can experience the benefits of immunotherapy, new technologies are […]
Our guest contributor Dr Neil Lamb continues his fortnighty Shareable Science Blog with an extract from the annual guidebook ‘A Year in Genetics as Told by Tomorrow’s Textbooks‘. Neil is the Vice President for Educational Outreach at the HudsonAlpha Institute for Biotechnology and Shareable Science will explore how genetics is relevant to people in their […]
Molecular Assemblies recently announced a $12.2M series A financing to advance their enzymatic DNA synthesis technology. We talked to Michael Kamdar, the CEO and president of Molecular Assemblies, to discuss how enzymatic DNA synthesis could revolutionise biotechnology. FLG: Can you introduce Molecular Assemblies? MK: Molecular Assemblies is a synthetic biology company founded in 2013, and […]
SAN DIEGO, October 1, 2019 — Molecular Assemblies, Inc., today announced that it has raised a $12.2 million Series A financing led by iSelect Fund and joined by existing investors, Agilent Technologies, Alexandria Venture Investments, and Keshif Ventures. The proceeds of the financing will be used to advance the company’s proprietary enzymatic DNA synthesis technology to […]
Researchers at the Key Laboratory of Synthetic Biology in Shanghai have used CRISPR to create a new species of yeast that only has a single giant chromosome.
Researchers have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell’s own genes, using gene editing technology CRISPRa.
A report has highlighted the potential misuses of synthetic biology for biological warfare with recommendations of how we might prepare for and prevent biological attacks.
Using genome-wide genetic approaches, researchers systematically screened for the loss of an additional gene that could rescue a genetic disease, and found it.
Researchers have synthesized the first artificial human prion, a dramatic development in efforts to combat a devastating form of brain disease that has so far eluded treatment and a cure.
J. Craig Venter shared on Twitter last week that he is retiring from Human Longevity, and returning to the J. Craig Venter Institute (JCVI) to continue his work.
Chemists have devised a way to rapidly synthesize and screen millions of novel proteins that could be used as drugs against Ebola and other viruses.
Researchers have discovered a way to greatly improve the accuracy of gene-editing technology by replacing the natural guide molecule it uses with a synthetic one called a bridged nucleic acid, or BNA.